A method for treatment of a headache disorder in a human subject, including selecting at least one treatment area in the nasal cavity of the human subject, said treatment area being selected from a posterior part of the nasal cavity or an anterior part of the nasal cavity, providing a device including a stimulation member arranged for vibration stimulation of the selected treatment area, and at least one expansion member provided with a channel having a plurality of openings arranged for fluid communication with the stimulation member, introducing the stimulation member into a nasal cavity of the human subject, expanding the stimulation member to a volume such that the stimulation member abuts against the tissue to exert a pressure on tissue of the selected treatment area and bringing the stimulation member to vibrate in the nasal cavity to impart vibrations to the selected treatment area, wherein the vibrations are imparted to a posterior part of the nasal cavity, to an anterior part of the nasal cavity, sequentially to a posterior and an anterior part of the nasal cavity; or simultaneously to a posterior and an anterior part of the nasal cavity.

A closed-loop implantable neurostimulator system for mitigating chronic pain, the closed-loop implantable neurostimulator system including a neuromodulation device comprising one or more electrodes configured to measure a physiological signal of a subject and deliver an electrical stimulation signal to a target area in the subject and a controller, in communication with the one or more electrodes, comprising a processor and a computer-readable memory storing a trained healthy computer model, the controller configured to analyze the physiological signal that is measured using the trained healthy computer model to identify a corrective electrical stimulation signal that, when delivered by the one or more electrodes to the target area, reduces pathological neuronal events in the target area while preserving acute pain response.

A method and system to treat headaches in a patient by performing surgery via at least one nostril. Data from a computer tomography scan of at least one nasal cavity and one sinus cavity of the patient and a completed headache questionnaire are matched to at least one nasal/sinus surgery plan to operate on at least one of: a nasal septum, at least one sinus cavity and at least one turbinate of the patient. The surgery plan is executed by installing a topical local anesthetic and decongestant onto the at least one turbinate forming an anesthetized decongested nasal cavity; infusing an anesthetic into the anesthetized decongested nasal cavity of the patient; dilating the at least one sinus ostium; incising at least one of: a first mucosal flap or a second mucosal flap of the nasal septum of the anesthetized decongested nasal cavity to expose deviated septal cartilage and bone; removing deviated cartilage and/or bone of the nasal septum; fracturing the at least one turbinate laterally away from the nasal septum; inspecting between the first mucosal flap and the second mucosal flap for a residual broken bone, a residual segment of cartilage or combinations thereof, surgically closing the first mucosal flap and the second mucosal flap of the nasal septum; and suctioning unwanted matter from the anesthetized decongested nasal cavity. An interactive system guides the surgery and provides a record thereof.

An MR Spectroscopy (MRS) system and approach is provided for measuring spectral information corresponding with propionic acid (PA), either alone or in combination with other measurements corresponding with other chemicals, to diagnose and/or monitor at least one of bacterial infection, such as associated with P. acnes, or conditions related thereto such as nociceptive pain associated with tissue acidity. An interfacing DDD-MRS signal processor receives output signals to produce a post-processed spectrum, with spectral regions corresponding with certain chemicals, including PA, then measured as biomarkers. A diagnostic processor derives a diagnostic value for each disc, and performs certain normalizations, based upon ratios of the spectral regions related to chemicals implicated in degenerative painful tissue pathology, such as PA and hypoxia markers of lactic acid (LA) and alanine (AL), and structural chemicals of proteoglycan (PG) and collagen or carbohydrate (CA).

Methods, systems, and apparatuses for determining an indication of pain of a user are disclosed. Electrodermal activity (EDA) data from a sensor may be received. The EDA data may be indicative of one or more physiological signals derived from sweat gland activity of the user. Index values may be determined based on the EDA data. The index values may be compared to a threshold to determine if one or more of the values of the index value satisfies the threshold. Satisfying the threshold may indicate a pain in the user, a pain level for the user and/or a source of pain within the user. The indication may be caused to be output so that the user or others may be informed of an objective measurement of the pain in the user.

Disclosed are methods and medical device systems for automated delivery of therapies for pain and determination of need for and safety of treatment. In one embodiment, such a medical device system may comprise a sensor configured to sense at least one body signal from a patient; and a medical device configured to receive a first sensed body signal from the sensor; determine a patient pain index based at least in part on said first sensed body signal; determine whether said patient pain index is above at least a first pain index threshold; determine a safety index based at least in part on a second sensed body signal; select a pain treatment regimen based on at least one of said safety index and or a determination that said pain index is above said first pain index threshold; and deliver said pain treatment regimen.

Methods and systems implement a pain assessment regularizing system to autonomously observe pained expressions and physiological measurements of a patient, in order to systematically collect data inputs which may be converted to pain assessment factors. The pain assessment regularizing system, by collecting this data, may combine it with clinical appraisals of pain intensity and patient self-reporting of pain intensity, weighing each factor appropriately in a manner sensitive to the progression of a patient care program, so as to lessen confounding effects of subjective pain assessment. The pain assessment regularizing system may generate a time series of regularized pain assessment factors, and further forecast a regularized pain assessment trend. A clinician may further operate the pain assessment regularizing system to review a visualization of both the time series and the forecast, providing the clinician with rigorously sampled and analytically predicted data which cannot be derived through manual and mental efforts.

The present invention provides a novel, comprehensive approach for the effective, safe and compassionate management of pain and opioid dependency, both in inpatient and outpatient settings, through the various stages of patient contact with the current healthcare system (e.g. initial encounter, treatment initiation, inpatient care, discharge, and post-discharge/chronic management) via innovative methods and treatment algorithms that provide consistent, repeatable and material advances in potential and high-risk, opioid-dependent patient management.

A virtual or augmented reality system is disclosed which is capable of both (i) evaluating prospective implantable neurostimulator patient candidates, and (ii) determining optimal stimulation settings for already-implanted neurostimulation patients. Physiological sensors are included with the system to provide objective measurements relevant to a patient's symptoms, such as pain in a Spinal Cord Stimulation (SCS) system. Such objective measurements are determined during the presentation of various virtual or augmented environments, and can be useful to determining which patients are suitable candidates to consider for implantation. Stimulation settings for already-implanted patients may be adjusted while presenting a virtual or augmented environment to the patient, with objective measurements being determined for each stimulation setting. Such objective measurements can then be used to determine optimal stimulation settings for the patient.

Various embodiments of the present invention provide methods, apparatus, systems, computing devices, computing entities, and/or the like for performing splinting activity detection. Certain embodiments of the present invention utilize systems, methods, and computer program products that perform splinting activity detection using at least one of splinting activity detection machine learning models, observed inspiration-expiration waveform pattern, and expected inspiration-expiration waveform patterns.